VW Factor Cleaving Prostease and Thrombotic Diseases

VW 因子裂解蛋白酶和血栓性疾病

• 批准号: 6911615
• 负责人: DOMINIC W. CHUNG
• 金额: $ 34.01万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-07-01 至 2007-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6911615
• 关键词: RNA splicing; autoantibody; blood disorder diagnosis; chemical cleavage; clinical research; diagnosis design /evaluation; enzyme activity; enzyme linked immunosorbent assay; enzyme structure; enzyme substrate; hemostasis; high performance liquid chromatography; human subject; immunologic assay /test; laboratory mouse; laboratory rabbit; messenger RNA; metalloendopeptidases; monoclonal antibody; protein purification; proteolysis; thrombocytopenic purpura; thrombosis; thrombospondins; tissue /cell culture; von Willebrand factor; western blottings

DESCRIPTION (provided by applicant): Thrombotic thrombocytopenic purpura (UP) is a thrombotic microangiopathic disorder that is associated with a deficiency of a protease activity that depolymerizes von Willebrand factor in plasma. Familial TIP is caused by a genetic deficiency of this protease, whereas acquired UP is caused by the presence of autoantibodies to the protease. This protease, which has been named vWF cleaving protease (VWFCP), is a metalloprotease and specifically cleaves the Tyrl 605-MetI 606 bond in the P2 domain of the vWF subunit. VWFCP has been purified to homogeneity, partially sequenced, and its cDNA has been cloned. VWFCP is a member of the ADAMTS family of metalloproteases and contains structural motifs such as disintegrin, Cys-rich, and thrombospondin-1 motifs, which are the defining characteristics of this family. In this application, we propose to (1) study the structure and function relationship of VWFCP, and compare the biochemical properties of VWFCP to its naturally occurring variant forms, which are synthesized as a result of alternative mRNA splicing; (2) develop alternative substrates, improved assays for the quantitative measurement of VWFCP activity, the level of VWFCP antigen in plasma, and the titer of autoantibodies to VWFCP. These studies would provide a better understanding of how this metalloprotease regulates the function of vWF and keeps a delicate balance between thrombosis and primary hemostasis. This understanding would provide a basis for devising alternative methods for treating familial and acquired UP.

描述（由申请人提供）：血栓性血小板减少性紫癜（UP）是一种血栓性微血管疾病，与血浆中分解血管性血友病因子的蛋白酶活性缺乏有关。家族性TIP是由该蛋白酶的遗传缺陷引起的，而获得性UP是由该蛋白酶自身抗体的存在引起的。该蛋白酶被命名为vWF切割蛋白酶（VWFCP），是一种金属蛋白酶，专门切割vWF亚基P2结构域的tyr605 - meti 606键。VWFCP已纯化至同源性，部分测序，cDNA已克隆。VWFCP是ADAMTS金属蛋白酶家族的一员，含有分解素、富含cys和凝血反应蛋白-1等结构基序，这些结构基序是该家族的决定性特征。在本应用中，我们建议(1)研究VWFCP的结构和功能关系，并比较VWFCP与其自然存在的变体形式的生化特性，这些变体形式是由于mRNA的选择性剪接而合成的；(2)开发替代底物，改进VWFCP活性、血浆中VWFCP抗原水平和VWFCP自身抗体滴度的定量测定方法。这些研究将更好地了解这种金属蛋白酶如何调节vWF的功能，并在血栓形成和原发性止血之间保持微妙的平衡。这种理解将为设计治疗家族性和获得性UP的替代方法提供基础。